Recursion Pharmaceuticals' REC-617 Phase 1/2 study shows safety and efficacy in solid tumors, with one patient experiencing stable disease, signaling potential therapeutic benefits.
Recursion Pharmaceuticals presented Phase 1/2 data on REC-617, a CDK7 inhibitor, at an AACR Special Conference, showcasing its potential in treating advanced solid tumors.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.